HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Peter Schafer Selected Research

apremilast

11/2021Phosphodiesterase-4 Inhibition Reduces Cutaneous Inflammation and IL-1β Expression in a Psoriasiform Mouse Model but Does Not Inhibit Inflammasome Activation.
1/2021Pharmacodynamic analysis of apremilast in Japanese patients with moderate to severe psoriasis: Results from a phase 2b randomized trial.
1/2020Large-scale Analyses of Disease Biomarkers and Apremilast Pharmacodynamic Effects.
12/2019Apremilast mechanism of efficacy in systemic-naive patients with moderate plaque psoriasis: Pharmacodynamic results from the UNVEIL study.
1/2019IL-12/IL-23p40 identified as a downstream target of apremilast in ex vivo models of arthritis.
6/2012Apremilast mechanism of action and application to psoriasis and psoriatic arthritis.
12/2011Disposition, metabolism and mass balance of [(14)C]apremilast following oral administration.
10/2010Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases.
1/2010Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Peter Schafer Research Topics

Disease

9Psoriasis (Pustulosis Palmaris et Plantaris)
11/2021 - 11/2005
7Neoplasms (Cancer)
11/2022 - 02/2003
7Multiple Myeloma
01/2018 - 01/2005
6Psoriatic Arthritis
11/2021 - 10/2010
5Heart Failure
02/2024 - 02/2021
4Inflammation (Inflammations)
12/2021 - 11/2009
3Arthritis (Polyarthritis)
11/2022 - 01/2010
2Fibrosis (Cirrhosis)
08/2023 - 01/2022
2Rheumatoid Arthritis
12/2022 - 01/2010
2Necrosis
12/2021 - 01/2010
2Myelodysplastic Syndromes (Myelodysplastic Syndrome)
10/2010 - 07/2008
2Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease)
11/2009 - 03/2006
2Weight Loss (Weight Reduction)
11/2009 - 03/2006
2Colonic Neoplasms (Colon Cancer)
01/2008 - 01/2005
1Myocardial Infarction
11/2023
1Pulmonary Fibrosis (Fibrosing Alveolitis)
08/2023
1Atherosclerosis
01/2022
1Aortic Valve Stenosis (Aortic Stenosis)
12/2021
1Oral Ulcer (Mouth Ulcer)
11/2021
1Heart Arrest (Cardiac Arrest)
02/2021
1Hematologic Diseases (Blood Diseases)
01/2021
1Systemic Lupus Erythematosus (Libman-Sacks Disease)
01/2021
1Ankylosing Spondylitis
01/2020
1Metabolic Diseases (Metabolic Disease)
05/2017
1Colorectal Neoplasms (Colorectal Cancer)
01/2011
1Venous Thromboembolism
01/2010
1Neutropenia
01/2010
1Experimental Arthritis
01/2010
1Disease Progression
11/2009
1Non-Hodgkin Lymphoma (Lymphosarcoma)
07/2008

Drug/Important Bio-Agent (IBA)

11Lenalidomide (CC 5013)FDA Link
05/2016 - 01/2005
9apremilastIBA
11/2021 - 01/2010
7Phosphodiesterase 4 InhibitorsIBA
11/2021 - 11/2005
6Biomarkers (Surrogate Marker)IBA
08/2023 - 12/2019
6Thalidomide (Thalomid)FDA Link
05/2016 - 02/2003
5Proteins (Proteins, Gene)FDA Link
11/2023 - 02/2003
4pomalidomideIBA
05/2016 - 07/2009
3CytokinesIBA
01/2021 - 11/2009
3iberdomideIBA
01/2021 - 01/2018
2Blood Proteins (Serum Proteins)IBA
02/2024 - 11/2023
2Mineralocorticoid Receptor AntagonistsIBA
11/2023 - 01/2022
2LigandsIBA
11/2022 - 01/2011
2InterleukinsIBA
12/2021 - 06/2012
2Interleukin-6 (Interleukin 6)IBA
12/2021 - 01/2020
2Type 4 Cyclic Nucleotide PhosphodiesterasesIBA
11/2021 - 01/2019
2Interleukin-17 (Interleukin 17)IBA
01/2020 - 12/2019
2Interleukin-12 (IL 12)IBA
01/2019 - 07/2008
2AntigensIBA
01/2011 - 07/2008
2AntibodiesIBA
01/2011 - 07/2008
2Immunomodulating AgentsIBA
01/2010 - 07/2009
2Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
01/2010 - 11/2009
2Cyclophosphamide (Cytoxan)FDA LinkGeneric
07/2008 - 01/2008
1Insulin (Novolin)FDA Link
11/2023
1Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
11/2023
1CreatinineIBA
11/2023
1JNK Mitogen-Activated Protein KinasesIBA
08/2023
1CC-90001IBA
08/2023
1Abatacept (Orencia)FDA Link
12/2022
1Anti-Citrullinated Protein AntibodiesIBA
12/2022
1Methotrexate (Mexate)FDA LinkGeneric
12/2022
1Antirheumatic Agents (DMARD)IBA
12/2022
1Collagen Type I (Type I Collagen)IBA
12/2022
1Interleukin-12 Subunit p40IBA
11/2022
1Phosphotransferases (Kinase)IBA
11/2022
1Peptides (Polypeptides)IBA
11/2022
1Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA
11/2022
1ChemokinesIBA
11/2022
1CXC ChemokinesIBA
11/2022
1Chemokine CCL7IBA
11/2022
1Glycoproteins (Glycoprotein)IBA
01/2022
1ApelinIBA
01/2022
1Liver X ReceptorsIBA
01/2022
1Spironolactone (Aldactone)FDA LinkGeneric
01/2022
1EndostatinsIBA
12/2021
1pro-brain natriuretic peptide (1-76)IBA
12/2021
1Lipocalin-2IBA
12/2021
1Fibroblast Growth Factors (Fibroblast Growth Factor)IBA
12/2021
1Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA
12/2021
1Brain Natriuretic Peptide (Natrecor)FDA Link
12/2021
1Matrix Metalloproteinase 7 (Matrilysin)IBA
12/2021
1OsteoprotegerinIBA
12/2021
1Syndecan-1 (Syndecan 1)IBA
12/2021
1InflammasomesIBA
11/2021
1Apolipoproteins MIBA
02/2021
1Transcription Factors (Transcription Factor)IBA
01/2021
1Interleukin-23 (Interleukin 23)IBA
12/2019
1AdipokinesIBA
12/2019
1C-Reactive ProteinIBA
05/2017
1Interleukin-10 (Interleukin 10)IBA
06/2012
1Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA
06/2012
1Tumor Biomarkers (Tumor Markers)IBA
01/2011
1Cetuximab (Erbitux)FDA Link
01/2011
1Trastuzumab (Herceptin)FDA Link
01/2011
1Collagen Type II (Type II Collagen)IBA
01/2010
1Fas Ligand Protein (Fas Ligand)IBA
11/2009
1Dexamethasone (Maxidex)FDA LinkGeneric
07/2009
1fludarabineIBA
07/2008
1IgG Receptors (Fc gamma RI)IBA
07/2008
1Immunoglobulin G (IgG)IBA
07/2008

Therapy/Procedure

3Therapeutics
01/2022 - 11/2005